Formulation and Evaluation of Extended Release Floating Matrix Tablet of Eperisone Hydrochloride by Direct Compression Method
Increased complications and costs of marketing of innovative drugs focused greater attention to the development of sustained release (SR) or controlled release (CR) drug delivery systems. Delivery systems extended release or controlled release rate can achieve predictable and reproducible, the extended duration of activity for the short time of life - drugs, reduced toxicity and dose reduction request, the optimized therapy and better patient compliance. It is controlled primarily by the type and the proportion of the polymers used in the preparation. Eperisone hydrochloride is a centrally acting muscle relaxant acting through poly and mono-synaptic reflexes in the spinal cord, exhibits vasodilator effect, increases blood flow and inhibits the pain reflex pathway. The objective of present work was to develop and evaluated oral extended release floating matrix tablet of eperisone HCl prepared by the method of direct compression, using hydroxy propyl methyl cellulose (HPMC K15, HPMC K4) and PVP K30 as matrix formation polymers. Sodium bicarbonate and citric acid was used as gas generating agents. The FTIR spectra of the eperisone HCl and other excipients alone and in combination show the compatibility of the drug and excipients. Nine formulations of different polymer percentages were formulated (F1-F9). Pre-compression parameters were evaluated. The influence of matrix forming agents and binary mixtures of them on eperisone HCl release was investigated. The formulated tablets were characterized by thickness and diameter, drug content, hardness, friability, uniformity of weight, In vitro buoyancy studies and dissolution rate studies. The formulated tablets had acceptable physicochemical characters. The data obtained from the in-vitro dissolution studies of optimized batch F7 were fitted in different models. The optimized formulation F7 showed 99.45±0.45% drug content and floating lag times of 65±4 sec. Drug release mechanism was found to be first order kinetics. Eperisone HCl floating tablets exhibited increased gastric residence time, there by improved bioavailability and therapeutic effect of the drug.
Keywords: Sustained release, Eperisone hydrochloride, Direct compression, Pre and post compression parameters
2. Vyas SP, Khar RK. Controlled drug delivery: concepts and advances. 1st ed. Vallabh Prakashan, New Delhi; 2002. p. 345-76.
3. Yeole PG. Floating drug delivery system: need and development. Indian J Pharm Sci 2005:67; 265-72.
4. Aurora S. Floating drug delivery: a review. AAPS Pharm Sci Tech 2005:47; 268-72.
5. Negi JS, Trivedi A, Khanduri P, Negi V, Kasliwal N. Effect of Bioadhesion on initial in vitro buoyancy of effervescent floating matrix tablets of ciprofloxacin HCl. J Adv Pharm Tech Res 2011;2:121-127.
6. Samyuktha Rani B, Vedha Hari BN, Brahma Reddy A, Punitha S, Devi P, Rajamanickam V. The recent developments on gastric floating drug delivery systems: A overview. Int J Pharm Tech Res 2010; 2:524-34.
7. Yadav A, Jain DK. In-vitro characterization of gastroretentive microballoons prepared by the emulsion solvent diffusion method. J Adv Pharm Tech Res 2010; 1:56-67.
8. Yadav A, Jain DK. Gastroretentive microballoons of metformin: Formulation development and characterization. J Adv Pharm Tech Res 2011; 2:51-5.
9. Viveksarathi K, Rajarajan R, Kannan K, Manavalan R. Dosage form design and evaluation of eperisone hydrochloride matrix film coated extended release tablets. Int J Pharm Pharm Sci. 2012; 4(2):575-81.
10. Cabitza P, Randelli P. Efficacy and safety of eperisone in patients with low back pain: a double blind randomized study. Eur Rev Med Pharmacol Sci. 2008; 12(4):229-35.
11. Chandanwale AS, Chopra A, Goregaonkar A, Medhi B, Shah V, Gaikwad S, et al. Evaluation of eperisone hydrochloride in the treatment of acute musculoskeletal spasm associated with low back pain: a randomized, double-blind, placebo-controlled trial. J Postgrad Med. 2011; 57(4):278.
12. Bose K. The efficacy and safety of eperisone in patients with cervical spondylosis: results of a randomized, double-blind, placebo-controlled trial. Methods Find Exp Clin Pharmacol. 1999; 21(3):209-14.
13. Melilli B, Piazza C, Vitale DC, Marano MR, Pecori A, Mattana P et al. Human pharmacokinetics of the muscle relaxant, eperisone hydrochloride by liquid chromatography–electrospray tandem mass spectrometry. Eur J Drug Metab Pharmacokinet 2011; 36(2):71.
14. Desai S, Bolton S. A floating controlled release system: in-vitro and in-vivo evaluation. J Pharm Res 1993:10; 1321-5.
15. Sakore S, Chakraborty B. Formulation and evaluation of enalapril maleate sustained release matrix tablets. Int J Pharm Biomed Res 2013; 4:21-6.
16. Udayakumar T, Suresh AG, Ubaidulla U. Formulation and evaluation of immediate and sustained release bilayered tablet with glibenclamide and metformin Hcl. Int J Res Dev Pharm Sci 2013;2:337-43.
17. Shashidhar P, Vidya Sagar G, Srikanth G. Design and in-vitro evaluation of metformin hydrochloride (SR) and glimepiride (IR) as bilayered tablets. Int J Pharm Chem Sci 2013; 2:780-92.
18. Sridhar Babu G, Vijay Kumar D, Aishwarya M, Malathy PS, Redya Naik R. Formulation and in vitro characterization of sustained release matrix tablets of metformin Hcl. J Glob Trends Pharm Sci 2014;5:2085-92.
19. Saluja V, Garg C. Once-daily sustained-release matrix tablets of metformin hydrochloride based on an enteric polymer and chitosan. J Pharm Educ Res 2013; 4:92-7.
20. Shishu G, Gupta N, Aggarwal N. A gastro-retentive floating delivery system for 5-fluorouracil. Asian J Pharm Sci. 2007; 2:143-49.
21. Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J Pharm Sci 1969; 58:1253-57.
22. Gibaldi M, Feldman S. Establishment of sink conditions in dissolution rate determinations: theoretical considerations and application to non disintegrating dosage forms. J Pharm Sci 1967; 56:1238-42.
23. Higuchi T. Mechanism of sustained-action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963; 52:1145-49.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).